NRX Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $20.8M | $27.6M |
| FY2022 | $2.8M | $7.4M | $20.1M |
| FY2023 | $9.2M | $-11.7M | $4.6M |
| FY2024 | — | $-23.2M | $1.4M |
| FY2025 | — | $-15.9M | $7.8M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $20.8M | $27.6M |
| FY2022 | $2.8M | $7.4M | $20.1M |
| FY2023 | $9.2M | $-11.7M | $4.6M |
| FY2024 | — | $-23.2M | $1.4M |
| FY2025 | — | $-15.9M | $7.8M |